Evidence map›Paper›PMID 42711266›Full record

ArticlePhytotherapy research : PTR2026

Protosappanin A Alleviates Atherosclerosis by Regulating the MDM2/GPX4 Axis-Mediated Endothelial Ferroptosis.

Jiamei Fu, Lin Zhu, Wenwei Yang, Mengnan Li, Zhixin Wu, Shude Sun, Yabin Zhou

Abstract read
In one paragraph

Article in Phytotherapy research : PTR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jiamei FuThe First Hospital Affiliated to Heilongjiang University of Chinese Medicine, Harbin, China.ORCID https://orcid.org/0009-0003-3597-6644
Lin ZhuHeilongjiang University of Chinese Medicine, Harbin, China.
Wenwei YangHeilongjiang University of Chinese Medicine, Harbin, China.
Mengnan LiHeilongjiang University of Chinese Medicine, Harbin, China.
Zhixin WuHeilongjiang University of Chinese Medicine, Harbin, China.
Shude SunHeilongjiang University of Chinese Medicine, Harbin, China.
Yabin ZhouThe First Hospital Affiliated to Heilongjiang University of Chinese Medicine, Harbin, China.ORCID https://orcid.org/0009-0004-5842-5527

Funding

Heilongjiang Provincial Postdoctoral Research Foundation LBH-Z22277Heilongjiang Provincial Scientific Research Project on Traditional Chinese Medicine ZHY2024-284National Natural Science Foundation Cultivation Program of the First Affiliated Hospital of Heilongjiang University of Chinese Medicine PY2025-038Young Scientific and Technological Innovation Capability Training Program under the Scientific Research Fund of Heilongjiang University of Chinese Medicine 2024-KYYWF-1372
6 · The paper itself

Abstract

Endothelial ferroptosis is a crucial pathogenic driver of atherosclerosis (AS) progression. Protosappanin A (PTA), a bioactive compound from Caesalpinia sappan L., protects cardiovascular vessels by regulating ferroptosis. However, whether PTA inhibits AS specifically through suppressing endothelial ferroptosis remains unclear. To address this, ApoE

Indexed as

AtherosclerosisFerroptosisPhospholipid Hydroperoxide Glutathione PeroxidaseProto-Oncogene Proteins c-mdm2PterocarpansAnimalsAortaCaesalpiniaDiet, High-FatHumansHuman Umbilical Vein Endothelial CellsLipid PeroxidationMaleMiceMice, Inbred C57BLglutathione peroxidase 4, mousePhospholipid Hydroperoxide Glutathione PeroxidaseProto-Oncogene Proteins c-mdm2Pterocarpansatherosclerosisendothelial cellferroptosisMDM2Protosappanin A

Identifiers

PMID42711266
PMCPMC13753677

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.